Clinical trials: Elderly Infection
Community-Acquired Pneumonia, Fraility
Frailty and Outcomes in Older Emergency Department Patients With Pneumonia
Pneumonia is one of the leading causes of infection-related mortality in the older population. Traditional severity scores used in emergency departments, such as the Pneumonia Severity Index (PSI) and CURB-65, primarily focus on…
- Conditions
- Community-Acquired Pneumonia, Fraility, Hospitalizations
- Trial name
- NCT07442656
- Testing
- Clinical frailty scale, Clinical Frailty Scale (CFS)
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ege University
Condylomata Acuminata
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
This phase Ⅱ clinical study was designed to evaluate the immunogenicity and safety of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged 18-55 years…
- Trial name
- NCT02710851
- Testing
- low dosage HPV Vaccine(1:1), low dosage HPV Vaccine(1:2), high dosage HPV Vaccine(1:1)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Influenza
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to…
- Trial name
- NCT00336453
- Testing
- Influenza Vaccination
- Where
- 3 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza…
- Trial name
- NCT01884519
- Testing
- Fluarix/Influsplit SSW® (2013-2014 season)
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers
The aim of the study is to investigate the safety and immunogenicity of a two-component intranasal vaccine for the prevention of COVID-19 in healthy volunteers 18-60 years old
- Trial name
- NCT05696067
- Testing
- Corfluvec component 1 low dose, Corfluvec component 2 low dose, Corfluvec component 1 high dose
- Where
- 2 sites in Russia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tatyana Zubkova
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profiles of the adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386698
- Testing
- Fluarix, adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infection, HPV Vaccine
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women…
- Conditions
- HPV Infection, HPV Vaccine, Cervical Cancer Prevention
- Trial name
- NCT06137352
- Testing
- Follow up
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Maternity and Child Health Hospital
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Adults
The purpose of the study is to obtain immunogenicity and safety data at different dose levels of an investigational H1N1 pandemic influenza vaccine in healthy adults 18 years of age and older.
- Trial name
- NCT00959465
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Community-dwelling Older Adults
Impact of Balance Training in Community-Dwelling Older Adults After Recovery From COVID-19
This research investigates the impact of balance training on improving functional performance and reducing fall risk in community-dwelling older adults who have recovered from COVID-19.
- Trial name
- NCT07002736
- Testing
- The Biodex training, Traditional balance training
- Where
- Saudi Arabia
- Volunteers
- 65 people
- Sponsor
- Cairo University
Dengue, Dengue Hemorrhagic Fever
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
The purpose of this study is to generate immunogenicity and safety data in preparation for efficacy studies in Latin America. Primary Objectives: To describe the immune response to dengue viruses before and after each vaccination…
- Trial name
- NCT01187433
- Testing
- Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus, NaCl 0.9%, Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HPV Infections
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
- Trial name
- NCT03085381
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
COVID-19
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have…
- Trial name
- NCT05636319
- Testing
- ABO1020
- Where
- 25 sites in Indonesia, Pakistan and 2 more
- Volunteers
- 14,168 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Influenza
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.
- Trial name
- NCT00316628
- Testing
- influenza vaccine
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Novartis
SARS-CoV2 Infection
Cellular Senescence and COVID-19 Long-Hauler Syndrome
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
- Trial name
- NCT04903132
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Influenza, Human
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07204964
- Testing
- Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A)
- Where
- 17 sites in United States, Belgium
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older…
- Trial name
- NCT03293498
- Testing
- NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21
- Where
- 3 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine
The aim of the study is to to assess the immunogenicity and safety of a quadrivalent influenza vaccine in a multi-dose presentation compared to a quadrivalent influenza vaccine in single-dose presentation, in children aged 6…
- Trial name
- NCT03391193
- Testing
- Multi-dose Quadrivalent Influenza Vaccine, Single-dose Quadrivalent Influenza Vaccine
- Where
- 3 sites in Mexico
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infection, Acute Coronary Syndrome
Association Between Levels of D-Dimer, Fibrinogen and PAI-1 in Elderly Patients With Infection and Occurrence of Cardio- and Cerebro-vascular Disease After Discharge
The association between the levels of d-dimer, fibrinogen and PAI-1 in plasma of elderly patients admitted to internal medicine departments because of infection and the occurrence of cardio- and cerebro-vascular disease after…
- Conditions
- Infection, Acute Coronary Syndrome, Cerebrovascular Disease
- Trial name
- NCT00512603
- Volunteers
- 52 people
- Sponsor
- Wolfson Medical Center
Hepatitis B
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
Comparison of adjuvanted hepatitis B vaccine to double dose of Engerix™-B in pre- /haemodialysis patients aged ≥15 years.
- Trial name
- NCT00383383
- Testing
- Hepatitis B adjuvanted vaccine, Engerix-B
- Where
- 3 sites in Czechia, Malaysia and 1 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline